European Archives - Page 1506 of 1573 - European Medical Journal

Music May Indeed Possess Charms to Soothe a Savage Breast

MUSIC may emerge as a treatment for heart conditions, according to researchers who have discovered that repeated musical phrases can affect the heart rate.

The impact of the Oncotype DX® Recurrence Score® on treatment decisions in breast cancer patients

The results of the Oncotype DX® Breast Cancer Assay are reported as a Recurrence Score® – a number ranging from 0 to 100. This number indicates the…

Molecular characterisation of kidney cancer and opportunities for targeted therapies

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Sumanta K. Pal, MD, of City of Hope Comprehensive Cancer Center, Duarte, CA…

Emerging targeted therapies in haematological malignancies

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Julie M. Vose, MD, MBA, of the University of Nebraska Medical Center, Omaha, NE…

New strategies in the treatment of multiple myeloma

Ola Landgren, MD, PhD, of Memorial Sloan Kettering Cancer Center, New York, NY, reviews the new data presented at the 2015 American Society of Clinical…

STRIDE: Phase 2 study of sipuleucel-T in metastatic castration-resistant prostate cancer

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Neal Shore, MD, FACS, of Atlantic Urology Clinics, Myrtle Beach, SC, discusses…

Julie M. Vose, MD, MBA, FASCO, elected ASCO President for 2015–2016 term

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, elected ASCO President for the 2015–2016 term, Julie M. Vose, MD, MBA, of the…

Towards targeted therapy of chronic lymphocytic leukaemia

Jacqueline Barrientos, MD, of North Shore-LIJ Cancer Institute, Lake Success, NY, summarises recent progress in the treatment of chronic lymphocytic…

Melanoma treatment update at ASCO 2015

Axel Hauschild, MD, of University of Schleswig-Holstein, Kiel, Germany, reviews the clinical trial data for new treatments in melanoma presented at the…

CheckMate 067: Phase 3 trial of nivolumab in melanoma

University of Nebraska Medical Center, Omaha, NE, discusses the phase 3 CheckMate 067 trial of nivolumab alone or combined with ipilimumab versus…